四种典型抑制剂验证药物转运体探针鸡尾酒
该随机开放交叉试验在45名健康男性中评估利福平、丙磺舒、维拉帕米和西咪替丁对四种转运体探针药代动力学的影响。结果显示相互作用方向与已知体外或临床数据基本一致,支持该鸡尾酒可作为评估转运体介导药物相互作用的敏感特异工具。
要点
- 单剂利福平使瑞舒伐他汀AUC0-tz增加248%、Cmax增加1025%。
- 丙磺舒使呋塞米AUC0-tz增加172%、Cmax增加23%。
- 西咪替丁使二甲双胍肾清除率降低26%。
核心结论
- 综合所有相互作用结果,该转运体鸡尾酒可被验证为药物开发中评估转运体介导药物相互作用的敏感且特异工具。
研究设计与样本
- 随机开放标签交叉试验,纳入45名健康男性受试者,比较鸡尾酒单用或联用单剂利福平、维拉帕米、西咪替丁或丙磺舒。
- 采用经验证的液相色谱-串联质谱法测定系列血浆和尿液中探针药物浓度以评估全身暴露。
主要发现
- 单剂利福平使瑞舒伐他汀AUC0-tz增加248%、Cmax增加1025%。
- 丙磺舒使呋塞米AUC0-tz增加172%、Cmax增加23%。
- 西咪替丁使二甲双胍肾清除率降低26%。
- 单剂维拉帕米对地高辛全身暴露的影响小于多剂研究预期,AUC0-tz不变、Cmax增加22%。
临床怎么用
- 该鸡尾酒可用于药物开发中评估转运体介导的药物相互作用。
- 临床解读转运体相互作用时需注意单剂与多剂抑制剂研究结果的差异。
局限性
- 研究仅纳入健康男性受试者,结果外推至女性、患者或其他人群需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: A novel cocktail containing four substrates of key drug transporters was previously optimized to eliminate mutual drug-drug interactions between the probes digoxin (P-glycoprotein substrate), furosemide (organic anion transporter 1/3), metformin (organic cation transporter 2, multidrug and toxin extrusion protein 1/2-K), and rosuvastatin (organic anion transporting polypeptide 1B1/3, breast cancer resistance protein). This clinical trial investigated the effects of four commonly employed drug transporter inhibitors on cocktail drug pharmacokinetics. METHODS: In a randomized open-label crossover trial in 45 healthy male subjects, treatment groups received the cocktail with or without single oral doses of rifampin, verapamil, cimetidine or probenecid. Concentrations of the probe drugs in serial plasma samples and urine fractions were measured by validated liquid chromatography-tandem mass spectrometry assays to assess systemic exposure. RESULTS: The results were generally in accordance with known in vitro and/or clinical drug-drug interaction data. Single-dose rifampin increased rosuvastatin area under the plasma concentration-time curve up to the last quantifiable concentration (AUC0-tz) by 248% and maximum plasma concentration (Cmax) by 1025%. Probenecid increased furosemide AUC0-tz by 172% and Cmax by 23%. Cimetidine reduced metformin renal clearance by 26%. The effect of single-dose verapamil on digoxin systemic exposure was less than expected from multiple-dose studies (AUC0-tz unaltered, Cmax + 22%). CONCLUSIONS: Taking all the interaction results together, the transporter cocktail is considered to be validated as a sensitive and specific tool for evaluating transporter-mediated drug-drug interactions in drug development. CLINICAL TRIAL REGISTRATION: EudraCT number 2017-001549-29.
引用
- Wiebe ST, Giessmann T, Hohl K, et al. Validation of a Drug Transporter Probe Cocktail Using the Prototypical Inhibitors Rifampin, Probenecid, Verapamil, and Cimetidine. Clin Pharmacokinet. 2020. PMID: 32504272. doi:10.1007/s40262-020-00907-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。